[1] A. F. CASY J. W. Ionisation constants and partition coefficients of some analgesically active 2-benzylbenzimidazole derivatives and related compounds[J]. Journal of Pharmacy and Pharmacology, 1966, 18 10: 677-683. DOI:
10.1111/j.2042-7158.1966.tb07782.x[2] PETER BLANCKAERT. Report on a novel emerging class of highly potent benzimidazole NPS opioids: Chemical and in vitro functional characterization of isotonitazene[J]. Drug Testing and Analysis, 2019, 12 4: 422-430. DOI:
10.1002/dta.2738[3] MARTHE M. VANDEPUTTE. Synthesis, Chemical Characterization, and μ-Opioid Receptor Activity Assessment of the Emerging Group of “Nitazene” 2-Benzylbenzimidazole Synthetic Opioids.[J]. ACS Chemical Neuroscience, 2021. DOI:
10.22541/au.160520665.59016513/v2[4] ISTVÁN UJVÁRY*. DARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles[J]. ACS Chemical Neuroscience, 2021, 12 7: 1072-1092. DOI:
10.1021/acschemneuro.1c00037[5] CHELSEA L SHOVER. Emerging Characteristics of Isotonitazene-Involved Overdose Deaths: A Case-Control Study.[J]. Journal of Addiction Medicine, 2021, 15 5: 429-431. DOI:
10.1097/adm.0000000000000775[6] LAURA B KOZELL. Pharmacologic Characterization of Substituted Nitazenes at μ, κ, and Δ Opioid Receptors Suggests High Potential for Toxicity.[J]. Journal of Pharmacology and Experimental Therapeutics, 2024: 219-228. DOI:
10.1124/jpet.123.002052